Commentary on "Lymphocytic colitis in the setting of teriflunomide use for relapsing multiple sclerosis"

被引：0
|
作者：
Bsteh, Gabriel [1 ]
Berger, Thomas [1 ]
机构：
[1] Med Univ Vienna, Dept Neurol, Wahringer Gurtel 18-20, A-1090 Vienna, Austria
来源：
MULTIPLE SCLEROSIS JOURNAL | 2020年 / 26卷 / 13期
关键词：
Teriflunomide; lymphocytic colitis; multiple sclerosis; adverse event; risk;
D O I：
10.1177/1352458520904546
中图分类号：
R74 [神经病学与精神病学];
学科分类号：
摘要：
引用
收藏
页码：1803 / 1804
页数：2
相关论文
共 50 条
  • [21] Teriflunomide: A Proposed Mechanism of Action in Patients with Relapsing Multiple Sclerosis
    Kieseier, B.
    Posevitz, V.
    Klotz, L.
    Kaplan, J.
    Wiendl, H.
    MULTIPLE SCLEROSIS JOURNAL, 2014, 20 (07) : 934 - 934
  • [22] The cost of teriflunomide in the treatment of relapsing- remitting multiple sclerosis
    Millar, J. Alasdair
    NEW ZEALAND MEDICAL JOURNAL, 2019, 132 (1490) : 36 - 41
  • [23] Teriflunomide for multiple sclerosis in real-world setting
    Elkjaer, M. L.
    Molnar, T.
    Illes, Z.
    ACTA NEUROLOGICA SCANDINAVICA, 2017, 136 (05): : 447 - 453
  • [24] Effectiveness of relapsing multiple sclerosis patients switching to teriflunomide following disease progression in a real-world setting
    Miravalle, A.
    Greene, N.
    Miller, R.
    Miller, T.
    Olson, J. M.
    Reddy, S. R.
    Chang, E.
    Fadaee, S.
    McGuey, L.
    Quach, C.
    Lublin, A.
    MULTIPLE SCLEROSIS JOURNAL, 2021, 27 (2_SUPPL) : 705 - 705
  • [25] Teriflunomide efficacy, safety and tolerability in patients with relapsing forms of multiple sclerosis
    Miller, Aaron E.
    NEURODEGENERATIVE DISEASE MANAGEMENT, 2013, 3 (05) : 467 - 483
  • [26] Teriflunomide for the treatment of relapsing-remitting multiple sclerosis: the Chieti experience
    di Ioia, M.
    Travaglini, D.
    Di Tommaso, V.
    Mancinelli, L.
    Pietrolongo, E.
    De Luca, G.
    Farina, D.
    Lugaresi, A.
    MULTIPLE SCLEROSIS JOURNAL, 2015, 21 : 754 - 754
  • [27] The ULTIMATE trials: are there advantages of ublituximab over teriflunomide in relapsing multiple sclerosis?
    Doggrell, Sheila A.
    EXPERT OPINION ON BIOLOGICAL THERAPY, 2022, 22 (11) : 1339 - 1343
  • [28] Teriflunomide for multiple sclerosis
    He, Dian
    Xu, Zhu
    Dong, Shuai
    Zhang, Hong
    Zhou, Hongyu
    Wang, Lu
    Zhang, Shihong
    COCHRANE DATABASE OF SYSTEMATIC REVIEWS, 2012, (12):
  • [29] Teriflunomide for the treatment of relapsing-remitting multiple sclerosis: patient preference and adherence
    Bayas, Antonios
    Maeurer, Mathias
    PATIENT PREFERENCE AND ADHERENCE, 2015, 9 : 265 - 274
  • [30] Outcomes of Ublituximab compared to Teriflunomide for relapsing multiple sclerosis: A meta-analysis
    Mukhtar, Humza
    Yasmeen, Uzma
    Siddiqa, Sania
    Sarfraz, Zouina
    Sarfraz, Azza
    MULTIPLE SCLEROSIS AND RELATED DISORDERS, 2022, 65
12345